Business development

Windtree is actively seeking opportunities to enter into one or more strategic alliances or other strategic transactions that would support development activities for istaroxime, the SERCA2a activators and the oncology platform aPKCi inhibitors. For rostafuroxin, we are currently seeking an out-licensing partner.”

As a company, Windtree is open to exploring additional mergers and/or acquisitions that would complement Windtree’s areas of focus or broaden Windtree’s potential to grow its business and potentially enhance its market value for stockholders and increase our capabilities to bring important new therapies to patients in need.

Inquiries for business development should be sent to [email protected]